GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

CUE · Jun 30, 2026

Cue Biopharma, Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 4[email protected]

Inspectable configuration

State dimensions

Filing0001193125-26-352128General Corporate

Capex intensity30thOwn-history percentile · N=20

Evidence method

Level · gp.fundamentals.capex_revenue_ratio

0.00% · OPTIONAL · VALID

Operating cash generation65thOwn-history percentile · N=20

Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

-368.21% · OPTIONAL · VALID

Revenue growth60thOwn-history percentile · N=20

Evidence method

Yoy · gp.fundamentals.revenue

166.66% · CORE · VALID

Operating margin30thOwn-history percentile · N=20

Evidence method

Level · gp.fundamentals.operating_margin

-1113.30% · CORE · VALID

R&D intensity60thOwn-history percentile · N=20

Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

622.15% · OPTIONAL · VALID

SBC intensity75thOwn-history percentile · N=20

Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

302.63% · OPTIONAL · VALID

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History29 statesSelf-history eligible

Period transition

What moved in the state?

Capex Intensity Decreased

Previous: 2.13%
Current: 0.00%
Delta: -2.13%

Cash Generation Decreased

Previous: -192.44%
Current: -368.21%
Delta: -175.77%

Growth Decreased

Previous: 1250.59%
Current: 166.66%
Delta: -1083.94%

Profitability Decreased

Previous: -94.14%
Current: -1113.30%
Delta: -1019.16%

R And D Intensity Increased

Previous: 121.30%
Current: 622.15%
Delta: 500.86%

Sbc Intensity Increased

Previous: 0.84%
Current: 302.63%
Delta: 301.78%

Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Sep 30, 2020

Similarity: 81%
Compared: 4 dimensions
Coverage: 67%

Profitability 25.6 · Sbc Intensity 19.4 · Cash Generation 15.0 · R And D Intensity 15.6

Dec 31, 2023

Similarity: 75%
Compared: 6 dimensions
Coverage: 100%

Growth 17.8 · Profitability 35.0 · Sbc Intensity 40.0 · Capex Intensity 10.0 · Cash Generation 5.0 · R And D Intensity 25.0

Mar 31, 2022

Similarity: 69%
Compared: 6 dimensions
Coverage: 100%

Growth 60.0 · Profitability 16.7 · Sbc Intensity 21.7 · Capex Intensity 0.8 · Cash Generation 36.4 · R And D Intensity 6.7

Dec 31, 2022

Similarity: 68%
Compared: 6 dimensions
Coverage: 100%

Growth 45.7 · Profitability 13.3 · Sbc Intensity 13.9 · Capex Intensity 20.0 · Cash Generation 53.2 · R And D Intensity 23.3

Mar 31, 2025

Similarity: 67%
Compared: 6 dimensions
Coverage: 100%

Growth 40.0 · Profitability 10.0 · Sbc Intensity 10.0 · Capex Intensity 50.0 · Cash Generation 45.0 · R And D Intensity 20.0

Research Graph

Related governed research

Analogous To · CUE state analogue 2 →Analogous To · CUE state analogue 1 →Analogous To · CUE state analogue 3 →Analogous To · CUE state analogue 4 →Compared To · Pharmaceutical Preparations peers →Analogous To · CUE state analogue 5 →Has State · Cue Biopharma, Inc. →Transitioned To · CUE Fundamental State →Transitioned To · CUE CAPEX_INTENSITY_DECREASED →Transitioned To · CUE CASH_GENERATION_DECREASED →Transitioned To · CUE GROWTH_DECREASED →Transitioned To · CUE PROFITABILITY_DECREASED →

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.